Kyntra BioLTS:0IL8 -1.94%50 Median PS Value is $0.00 as of Jul. 09, 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 50/100 and a GF Value™ of $5.70 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 274 Biotechnology companies, Kyntra Bio ranks worse than 364963.14% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Kyntra Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.839. Kyntra Bio's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2026-07-09), Kyntra Bio's share price is $7.4531. Kyntra Bio's Median PS Value is $0.00. Therefore, Kyntra Bio's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Kyntra Bio's Median PS Value or its related term are showing as below:
LTS:0IL8's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.645 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Kyntra Bio (LTS:0IL8) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Kyntra Bio's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
7.4531
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio Median PS Value Related Terms
Kyntra Bio Median PS Value Historical Data
* Premium members only.
The historical data trend for Kyntra Bio's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IL8 vs TVGN, PSTV, GRDX: Median PS Value Comparison
For the Biotechnology subindustry, Kyntra Bio's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyntra Bio Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyntra Bio's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Kyntra Bio's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Kyntra Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.839.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio (LTS:0IL8) has a Median PS Value of $0.00 as of Jul. 09, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Kyntra Bio and its competitors. According to the industry distribution chart, Kyntra Bio ranks #999999 out of 274 companies in the Biotechnology industry.
Is Kyntra Bio's Median PS Value too high?
Kyntra Bio's current Median PS Value is $0.00. Based on the distribution chart, Kyntra Bio ranks #999999 out of 274 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kyntra Bio has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Median PS Value compare to TVGN and PSTV?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #999999 out of 274 companies for Median PS Value. This places Kyntra Bio in the lower half of its industry. The industry median Median PS Value is 0.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.65, based on 274 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Kyntra Bio and its competitors. For the Biotechnology industry, the median Median PS Value is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyntra Bio's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.70, compared to a current price of $7.45 — trading 30.8% above its estimated fair value. The current Median PS Value is $0.00. Kyntra Bio's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Median PS Value is $0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?
Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued.
The current stock price of $7.45 is trading 30.8% above its estimated GF Value™ of $5.70.
GuruFocus considers Kyntra Bio to be Significantly Overvalued.
Key valuation signals for LTS:0IL8:
Median PS Value: $0.00
GF Value™: $5.70 vs. price of $7.45 (30.8% above fair value)
No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score
Get the complete analysis for LTS:0IL8
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IL8 has been successfully added to your 
